摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,7-萘啶-1(2H)-酮盐酸盐 | 369648-60-2

中文名称
2,7-萘啶-1(2H)-酮盐酸盐
中文别名
——
英文名称
1-hydroxy-2,7-naphthyridine hydrochloride salt
英文别名
2,7-Naphthyridin-1-ol hydrochloride;2H-[2,7]Naphthyridin-1-one hydrochloride;2H-2,7-naphthyridin-1-one;hydrochloride
2,7-萘啶-1(2H)-酮盐酸盐化学式
CAS
369648-60-2
化学式
C8H6N2O*ClH
mdl
MFCD15474922
分子量
182.609
InChiKey
FZVQCDOFCWVJJR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.11
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    42
  • 氢给体数:
    2
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2,7-萘啶-1(2H)-酮盐酸盐三氯氧磷 作用下, 以 二氯甲烷 为溶剂, 反应 2.0h, 以85.5%的产率得到1-氯-2,7-萘啶
    参考文献:
    名称:
    Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives
    摘要:
    本发明涉及一种制备1-卤代-2,7-萘啶衍生物的方法(I),其中X为Cl或Br;该方法包括以下步骤:(i)将式(A)的3-氰基-4-甲基吡啶衍生物与式(II)的化合物在N,N-二甲基甲酰胺二C1-6烷基缩醛的存在下反应,得到式(III)的恩酰衍生物;(ii)将式(III)的恩酰衍生物环化,得到式(IV)的化合物;(iii)将式(IV)的化合物与卤化剂反应,得到式(I)的化合物。
    公开号:
    US20090221828A1
  • 作为产物:
    描述:
    4-[2-pyrrolidin-1-ylvinyl]nicotinonitrile盐酸 作用下, 以 为溶剂, 反应 1.17h, 以90%的产率得到2,7-萘啶-1(2H)-酮盐酸盐
    参考文献:
    名称:
    Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives
    摘要:
    本发明涉及一种制备1-卤代-2,7-萘啶衍生物的方法(I),其中X为Cl或Br;该方法包括以下步骤:(i)将式(A)的3-氰基-4-甲基吡啶衍生物与式(II)的化合物在N,N-二甲基甲酰胺二C1-6烷基缩醛的存在下反应,得到式(III)的恩酰衍生物;(ii)将式(III)的恩酰衍生物环化,得到式(IV)的化合物;(iii)将式(IV)的化合物与卤化剂反应,得到式(I)的化合物。
    公开号:
    US20090221828A1
点击查看最新优质反应信息

文献信息

  • [EN] PHENYLALANINE ENAMIDE DERIVATIVES<br/>[FR] DERIVES DE PHENYLALANINE ENAMIDE
    申请人:CELLTECH R&D LTD
    公开号:WO2004007494A1
    公开(公告)日:2004-01-22
    Phenylalanine enamide derivatives of formula (1) are described, wherein R1 is a -CH(CH3)2, -(CH2)2CH3; -CH2C(CH3)3, -CH2CH2OH, -CH2CH2OCH3, -CH2CH2OCH2CH2OH, -CH2CH2OCH2CH2OCH3, formula (A) group; and the salts, solvates and N-oxides thereof. Compounds according to the invention are potent and selective inhibitors of α4 integrins. The compounds are of use in modulating cell adhesion and in particular are of use in the prophylaxis and treatment of diseases or disorders including inflammation in which the extravasation of leukocytes plays a role and the invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such diseases or disorders.
    公式(1)中描述了苯丙氨酸烯酰胺衍生物,其中R1为-CH(CH3)2,-(CH2)2CH3;-CH2C(CH3)3,-CH2CH2OH,-CH2CH2OCH3,-CH2CH2OCH2CH2OH,-CH2CH2OCH2CH2OCH3,公式(A)基团;以及它们的盐、溶剂合物和N-氧化物。根据本发明的化合物是α4整合素的有效和选择性抑制剂。这些化合物可用于调节细胞粘附,特别是可用于预防和治疗包括白细胞外渗在内的炎症等疾病或紊乱,本发明还涉及这种用途以及用于制造用于治疗此类疾病或紊乱的药物的化合物的用途。
  • [EN] PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES<br/>[FR] PROCEDE DE PREPARATION DE DERIVES DE PHENYLALANINE-ENAMIDE
    申请人:CELLTECH R&D LTD
    公开号:WO2004007428A1
    公开(公告)日:2004-01-22
    A process for the preparation of a class of phenylalanine enamide derivatives is described formula (1) wherein: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a linker group selected from -N(R4)- [where R4 is a hydrogen atom or an optionally substituted straight or branched C1-6alkyl group], -CON(R4)-, or -S(O)2N(R4)-; R1 is a carboxylic acid (-CO2H) or a derivative or biostere thereof; R2 is a hydrogen atom or a C1-6alkyl group; Rx, Ry and Rz which may be the same or different is each an atom or group -L1(Alk1)n(R3)v; and the salts, solvates, hydrates and N-oxides thereof; which comprises reacting a compound of formula (2): wherein: Qa is a group -N(R4)H; and the salts, solvates, hydrates and N-oxides thereof; with a compound Ar1W wherein W is a group selected from X1 (wherein X1 is a leaving atom or group), -COX2 (wherein X2 is a halogen atom or a -OH group) or -SO2 X3 (in which X3 is a halogen atom).
    描述了一种制备苯丙氨酸烯酰胺衍生物类的过程,其化学式为(1)其中:Ar1是一个可选择取代的芳香族或杂芳族基团;L2是从-N(R4)- [其中R4是氢原子或可选择取代的直链或支链C1-6烷基基团],-CON(R4)-或-S(O)2N(R4)-中选择的连接基团;R1是一个羧酸(-CO2H)或其衍生物或生物立体异构体;R2是一个氢原子或一个C1-6烷基基团;Rx、Ry和Rz可以相同也可以不同,每个都是一个原子或基团-L1(Alk1)n(R3)v;以及其盐、溶剂合物、水合物和N-氧化物;所述过程包括将化合物(2)与化合物Ar1W反应,其中:Qa是一个基团-N(R4)H;以及其盐、溶剂合物、水合物和N-氧化物;其中W是从X1(其中X1是一个脱离原子或基团),-COX2(其中X2是卤原子或一个-OH基团)或-SO2X3(其中X3是卤原子)中选择的基团。
  • Enamine derivatives
    申请人:——
    公开号:US20020037909A1
    公开(公告)日:2002-03-28
    Enamine derivatives of formula (1) are described: 1 wherein R 1 is a group Ar 1 L 2 Ar 2 Alk- in which Ar 1 is an aromatic or heteroaromatic group, L 2 is a covalent bond or a linker atom or group, Ar 2 is an arylene or heteroarylene group and Alk is a chain —CH 2 —CH(R)—, —CH═C(R)— or 2 in which R is a carboxylic acid or a derivative or biostere thereof; R 2 is a hydrogen atom or a C 1-6 alkyl group; Cy is a cycloaliphatic or heterocycloaliphatic ring in which X is a N atom or a C(R w ) group; R x is a oxo, thioxo, or imino group; R w and R z is each a hydrogen atom or optional substituent; provided that Cy is not a cyclobutenedione group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders, or disorders involving the inappropriate growth or migration of cells.
    描述了公式(1)的Enamine衍生物:其中R1是Ar1L2Ar2Alk-中的一个基团,其中Ar1是芳香族或杂环芳基,L2是共价键或连接原子或基团,Ar2是芳基或杂环芳基,Alk是链—CH2—CH(R)—,—CH═C(R)—或其中R是羧酸或其衍生物或生物类似物;R2是氢原子或C1-6烷基基团;Cy是环脂环或杂环脂环,其中X是N原子或C(Rw)基团;Rx是氧化、硫代氧化或亚胺基团;Rw和Rz分别是氢原子或可选取代基;前提是Cy不是环丁二酮基团;以及它们的盐、溶剂合物、水合物和N-氧化物。这些化合物能够抑制整合素与其配体的结合,并可用于预防和治疗免疫或炎症性疾病,或涉及细胞异常生长或迁移的疾病。
  • 2-Arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
    申请人:Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
    公开号:US06727269B1
    公开(公告)日:2004-04-27
    The invention concerns novel 2-arylimino-2,3-dihydrothiazole derivatives of general formula (I), their preparation methods and their use as medicines, in particular for treating pathological conditions or diseases wherein one (or several) somatostatin receptors is/are involved. Said pathological conditions include in particular acromegaly, pituitary adenoma or endocrine gastroenteropanceatic tumors including the carcinoid syndrome, and gastrointestinal bleeding. In general formula (I), R1 represents in particular an alkyl, aralkyl, cyclohexyl radical optionally substituted by an amino radical or R1 represents a —C(R11)(R12)—CO—R10 radical wherein R11 represents H, R12 represents in particular H, carbocyclic or heterocyclic alkyl, cycloalkyl or aralkyl and R10 represents in particular an aminoalkylamino radical; R2 represents a carcyclic or heterocyclic aryl radical optionally substituted; R3 represents in particular COR5 or a carbocyclic or heterocyclic alkyl, adamantyl, aryl radical optionally substituted, carbocyclic or heterocyclic aralkyl optionally substituted on the aryl group; and R5 represents a radical fixed by a nitrogen atom to the group CO.
    该发明涉及一种新型的2-芳基亚胺基-2,3-二氢噻唑衍生物,其通用式为(I),以及它们的制备方法和它们作为药物的用途,特别是用于治疗某种病理条件或疾病,其中一个(或多个)生长抑素受体参与。所述的病理条件特别包括肢端肥大症、垂体腺瘤或内分泌胃肠胰腺肿瘤,包括类癌综合征和胃肠道出血。在通用式(I)中,R1特别表示一种烷基、芳基烷基、环己基基团,该基团可选择地被氨基基团取代,或者R1表示一个—C(R11)(R12)—CO—R10基团,其中R11表示H,R12特别表示H、碳环或杂环烷基、环烷基或芳基烷基,R10特别表示一种氨基烷基氨基基团;R2表示一个碳环或杂环芳基基团,该基团可选择地被取代;R3特别表示COR5或一个碳环或杂环烷基、金刚烷基、芳基基团,该基团可选择地被取代,碳环或杂环芳基烷基,在芳基基团上可选择地被取代;R5表示由氮原子固定的基团,与羰基结合。
  • Phenylalanine enamide derivatives
    申请人:——
    公开号:US20020169336A1
    公开(公告)日:2002-11-14
    Phenylalanine enamide derivatives of formula (1) are described: 1 wherein R 1 is a group Ar 1 L 2 Ar 2 Alk- in which: Ar 1 is an optionally substituted aromatic or heteroaromatic group; L 2 is a covalent bond or a linker atom or group; Ar 2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain —CH 2 —CH(R)13 , —CH═C(R)— or 2 in which R is a carboxylic acid (—CO 2 H) or a derivative or biostere thereof; X is an —O— or —S— atom or —N(R 2 )— group in which: R x , R y and R z which may be the same or different is each a hydrogen atom or an optional substituent; or R z is an atom or group as previously defined and R x and R y are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.
    描述了公式(1)的苯丙氨酸烯酰胺衍生物:其中R1是Ar1L2Ar2Alk-中的一种基团,其中:Ar1是可选择取代的芳香族或杂环芳基;L2是一个共价键或连接原子或基团;Ar2是可选择取代的芳基或杂芳基;Alk是一个链-CH2-CH(R)13,-CH═C(R)-或2其中R是羧酸(-CO2H)或其衍生物或生物立体异构体;X是一个-O-或-S-原子或-N(R2)-基团,其中:Rx、Ry和Rz可能相同也可能不同,分别是氢原子或可选择取代基;或Rz是如前所定义的原子或基团,Rx和Ry结合在一起形成一个可选择取代的螺环联接的环脂肪族或杂环脂肪族基团;以及它们的盐、溶剂合物、水合物和N-氧化物。这些化合物能够抑制整合素与其配体的结合,并可用于预防和治疗免疫或炎症性疾病或涉及细胞不当生长或迁移的疾病。
查看更多